PUMA BIOTECHNOLOGY, INC. Tangible Asset Impairment Charges
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Tangible Asset Impairment Charges of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:TangibleAssetImpairmentCharges · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. tangible asset impairment charges for the quarter ending 2026-06-30 was $0.00.
- PUMA BIOTECHNOLOGY, INC. tangible asset impairment charges for the quarter ending 2026-03-31 was $0.00.
- PUMA BIOTECHNOLOGY, INC. tangible asset impairment charges for the quarter ending 2025-09-30 was $0.00.
- PUMA BIOTECHNOLOGY, INC. tangible asset impairment charges for the quarter ending 2025-06-30 was $0.00.
- PUMA BIOTECHNOLOGY, INC. tangible asset impairment charges for fiscal 2025 was $0.00.
- PUMA BIOTECHNOLOGY, INC. tangible asset impairment charges for fiscal 2024 was $0.00.
| Period end | Tangible Asset Impairment Charges 3 month | Tangible Asset Impairment Charges 6 month | Tangible Asset Impairment Charges 9 month | Tangible Asset Impairment Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 2 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |